Isolation of Rare Circulating Tumor Cells Sunitha Nagrath et al. Presentation.

Slides:

Advertisements

Similar presentations

CirculatingTumor Cells: Toward a clinical benefit? Giuseppe Naso MD, PhD, Associated Professor of Medical Oncology Director of Traslational Oncology Paola.

Advertisements

Shyamala Maherswaran, Ph.D. et al. Sarah Gomez and Rachael Holmes Detection of Mutations in EGFR in Circulating Lung-Cancer Cells.

R5 洪逸平 SUPERVISOR 趙大中醫師. Breast Cancer  The most prevalent cancer in female  Mortality 4 th in Taiwan.

Circulating Tumor Cells (CTCs) - Detection and isolation technologies.

 2013 Genentech USA, Inc. All rights reserved. Disclosure/Disclaimer The Molecular Biomarkers in Cancer (MBiC) slide presentation is not an independent.

Circulating Tumor Cells

Master in Advanced Genetics

Detection of Mutations in EGFR in Circulating Lung-Cancer Cells Colin Reisterer and Nick Swenson S. Maheswaran et al. The New England Journal of Medicine.

Circulating Tumor Cells Minetta C. Liu, MD Associate Professor of Medicine and Oncology Director, Translational Breast Cancer Research Lombardi Comprehensive.

Clinical Utility of CellSearch Richard A. Bender,MD,FACP Medical Director-Hematology/Oncology Quest Diagnostics Nichols Institute.

Isolation of Rare Circulating Tumor Cells in Cancer Patients by Microchip Technology Toner, et al Stephanie Bachar Matt Luchette.

Supplementary Figure 1. Supplementary Figure 2 All patients CharacteristicN% Median Age of patients 58 yrs ER Positive Negative PR Positive.

Isolation of rare circulating tumor cells in cancer patients by microchip technology Nagrath & Sequist et al. (2007) Journal Presentation Brigitte Morales.

Circulating tumor cells (CTCs) in blood of breast cancer patients: Cytological detection and technical characterization Enrica Bresaola, Mara Jo Miller,

Tiffany Marshall Saint Mary-of-the-Woods College Tim McKnight Measurement Science and Systems Engineering Division Dr. Kristina Thiagarajan Computing and.

Tiffany M. Marshall Saint Mary-of-the-Woods College Mentors : Tim McKnight Measurement Science and Systems.

Preliminary Validation of a Multispectral Image Analysis Application for Confirmation of Isolated Tumor Cells in Axillary Lymph Nodes from Breast Cancer.

OF COLOREATAL CANCER USING SEROLOGIC TUMOR MARKERS DIAGNOSIS & MANAGEMENT.

Towards a fast, efficient assay for isolating circulating tumor cells

Phase I Trial of Sorafenib in High-Risk Hepatocellular Carcinoma (HCC) Patients After Liver Transplantation (LT) AB Siegel, R Hidalgo, D Tsushima, J Zaretsky,

 Cancer is a group of more than 100 diseases that develop over time › Involve the uncontrolled division of the body’s cells  Cancer is the 2 nd leading.

When will the diagnosis of Circulating tumor cells (CTC) help to patients? Martin Pešta, Ondřej Topolčan Department of Internal Medicine II, Faculty of.

A novel method for the in vivo isolation of circulating tumor cells from peripheral blood of cancer patients using a functionalized and structured medical.

By: John Rawls.  There are over 100 types of Cancer  Over 7 million deaths a year (2004)  Makes up over 13% of the world’s deaths each year  The disease.

Pathology Reports Nicole Draper, MD.

Microtube Device for Selectin- Mediated Capture of Viable Circulating Tumor Cells from Blood A.D. Hughes, J. Mattison, L.T. Western, J.D. Powderly, B.T.

Sunitha Nagrath, Lecia V. Sequist, Shyamala Maheswaran, Daphne W. Bell, Daniel Irimia, Lindsey Ulkus, Matthew R. Smith, Eunice L. Kwak, Subba Digumarthy,

AGA/ASCO/ASTRO/SSO Gastrointestinal Cancers Symposium Orlando, FL January 26, 2008 Circulating tumor cells: are they predictive markers? Neal J. Meropol,

Kyle Rafferty Biomedical Engineering. Overview  What are CTC’s?  Why is detection important?  Older methods of detection Immunomagnetic beads Flat.

Pulmonary Venous Blood Sampling Significantly Increases the Yield of Circulating Tumor Cells in Early Stage Lung Cancer Reddy RM, Murlidhar V 2, Zhao L.

Integrated barcode chips for rapid, multiplexed analysis of proteins in microliter quantities of blood Jenny Zhou and Anne Ye Fan, Vermesh, et.

“Isolation of rare circulating tumour cells in cancer patients by microchip technology” Nagrath et al. Nature 2007 Peter Bojo.

A Circulating Tumor Cell (CTC) Assay for Tracking Treatment Response in Glioma Melody Ju, Gary D Kao, David Steinmetz, Dana Patsch, Michelle Alonso-Basanta,

AmirAli H. Talasaz, Ashley A. Powell, David E. Huber, James G. Berbee, Kyung-Ho Roh, Wong Yu, Wenzhong Xiao, Mark M. Davis, R. Fabian Pease, Michael N.

Circulating tumor cell monitoring, isolation and culture from a patient with metastatic triple negative breast cancer for drug screening and creation of.

CAMELYON17: Moving the challenge to patient level

TBCRC (the translational breast cancer research consortium) 005 Prospective study

The NEW ENGLNAD JOURNAL of MEDICINE 368;18 MARCH 28, 2013

سرطان الثدي Breast Cancer

Van’t Veer et al, Nature 415: (2002)

Opportunities and Challenges for Pancreatic Circulating Tumor Cells

The CTC-Chip: An Exciting New Tool to Detect Circulating Tumor Cells in Lung Cancer Patients Lecia V. Sequist, MD, MPH, Sunitha Nagrath, PhD, Mehmet.

a. Good prognosis Poor prognosis Metastasis b. Good prognosis

The Single-Cell Yin and Yang of Live Imaging and Transcriptomics

A subgroup analysis of a large multicenter study

Circulating Tumor Cells in Pulmonary Venous Blood of Primary Lung Cancer Patients Yoshitomo Okumura, MD, Fumihiro Tanaka, MD, PhD, Kazue Yoneda, Masaki.

Volume 4, Issue 1, Pages 4-6 (July 2003)

Emerging Strategies for Treating Brain Metastases from Breast Cancer

Clinical applications of CTCs and ctDNA as liquid biopsy for personalized medicine. Clinical applications of CTCs and ctDNA as liquid biopsy for personalized.

Capture of CK+ and CK− complex aneuploid CTCs in breast, ovarian, or colorectal cancer. Capture of CK+ and CK− complex aneuploid CTCs in breast, ovarian,

Volume 5, Issue 3, Pages e4 (September 2017)

Fig. 1. scRNA-seq applications in cancer medicine.

Volume 145, Issue 2, Pages (May 2017)

Circulating Melanoma Cell Subpopulations: Their Heterogeneity and Differential Responses to Treatment Elin S. Gray, Anna L. Reid, Samantha Bowyer, Leslie.

Expanded Circulating Tumor Cells from a Patient with ALK-Positive Lung Cancer Present with EML4-ALK Rearrangement Along with Resistance Mutation and Enable.

ADAM8 knockdown profoundly decreases orthotopic tumor formation, CTC spread and metastasis A–DStable ADAM8 KD (shA8) clones were characterized in vitro.

Socs1 KD tumors show alterations in multiple populations.

Fig. 4 Click Chips combined with RT-ddPCR analysis can be used to monitor dynamic changes in CTC count and CTC-derived ALK/ROS1 rearrangements in patients.

A, ATP production by PC3 prostate cancer cells after treatment with oligonucleotide/Lipofectin complexes. a, ATP production by PC3 prostate cancer cells.

H19 was essential for cancer metastasis.

Single-cell analyses to tailor treatments

Distributions of CD4, Th1, and Th2 in adults (n = 16; A) and children (n = 50; B). Distributions of CD4, Th1, and Th2 in adults (n = 16; A) and children.

Binding and antiproliferative effects of ANG4043 and anti-HER2 mAbs on tumor cells. Binding and antiproliferative effects of ANG4043 and anti-HER2 mAbs.

Immunohistochemical staining for FOXO3a of breast cancer tumor tissues

Tumor cell clusters arise from cellular aggregation.

Increased levels of acetylated histone H3 are observed in normal PBMCs and circulating tumor cells obtained from patients post-depsipeptide treatment.

Location of the ER mutations and frequencies per cohort.

Fig. 5 Proportions of EpCAM+ systemic tumor cells correlate with the clinical outcome of patients with MBC. Proportions of EpCAM+ systemic tumor cells.

Empty basement membrane sleeves and endothelial sprouts.

Presentation transcript:

Isolation of Rare Circulating Tumor Cells Sunitha Nagrath et al. Presentation by: Keara Darragh, Matthew Faw, and Will Plautz

Overview of Metastasis and CTCs Circulating tumor cells (CTCs) Likely the origin of intractable metastatic disease 1 CTC : 10^9 haematologic cells in the blood of cancer patients

CTC chip better than existing methods Gross prognostic tool (high/low risk) Isolates fewer CTCs with very low purity (<1%) and yield Multiple bulk semi- automated preparatory steps First microfluidic device that can successfully isolate viable cells from milliliter volumes of whole blood High sensitivity, selectivity, and yield Single step Circulating Tumor Cell (CTC) Chip Immunomagnetic-bead purification

What is Microfluidics? Deals with small volumes (fL, pL, nL, µL) of fluids Generally processed in a way that moves, mixes, or separates the contents Microfluids act differently Surface tension and low Reynolds number become larger factors in the system Different types of microfluidics Dealing with continuous-flow today

What is Microfluidics? Deals with small volumes (fL, pL, nL, µL) of fluids Generally processed in a way that moves, mixes, or separates the contents Microfluids act differently Surface tension and low Reynolds number become larger factors in the system Different types of microfluidics Dealing with continuous-flow today

What is Microfluidics? Deals with small volumes (fL, pL, nL, µL) of fluids Generally processed in a way that moves, mixes, or separates the contents Microfluids act differently Surface tension and low Reynolds number become larger factors in the system Different types of microfluidics Dealing with continuous-flow today

How Does the Chip Capture Circulating Tumor Cells? 25 mm x 66 mm silicon chip 78,000 microposts epCAM antibodies

CTC Isolating Microfluidic Device 25mm

Staining to Assess Purity Stains are used in order to identify malignant cells from healthy cells. Malignant cells look different Large cellular size Relatively large nuclei Visible nucleoli

Results and Applications Successfully identified CTCs in 115/116 samples Approximately 50% purity CTCs isolated (per ml): NSCLC: 5-1,281 Breast: Monitor cancer treatment response

Results and Applications Successfully identified CTCs in 115/116 samples Approximately 50% purity CTCs isolated (per ml): NSCLC: 5-1,281 Breast: Monitor cancer treatment response

Conclusion First microfluidic device that can successfully process milliliter volumes of whole blood High sensitivity, selectivity, and yield Single step Isolation of viable cells Allows for real time monitoring of cancer progression in a non-invasive manner